|
JAK1 (Janus Kinase 1) Assay Kit
|
Buy from Supplier |
|
Proteintech
jak1 ![]() Jak1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/janus+kinase+jak+1/JAK1+Antibody/bio_rxiv__2025__07__11__662357-213-9-10 Average 96 stars, based on 1 article reviews
jak1 - by Bioz Stars,
2026-10
96/100 stars
|
Buy from Supplier |
|
MedChemExpress
jak1 ![]() Jak1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/janus+kinase+jak+1/JAK1%2C+Human/pmc12484741-300-18-19 Average 93 stars, based on 1 article reviews
jak1 - by Bioz Stars,
2026-10
93/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
anti cd45 microbeads ![]() Anti Cd45 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/janus+kinase+jak+1/Jak1+Antibody%2C+anti-human%2Fmouse%2Frat%2C+REAfinity/bio_rxiv__2025__01__17__633599-186-14-18 Average 93 stars, based on 1 article reviews
anti cd45 microbeads - by Bioz Stars,
2026-10
93/100 stars
|
Buy from Supplier |
|
BPS Bioscience
jak1 assay kit ![]() Jak1 Assay Kit, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/janus+kinase+jak+1/JAK1+(Janus+Kinase+1)+Assay+Kit/10__3389_slash_fphar__2025__1591394-140-1-5 Average 94 stars, based on 1 article reviews
jak1 assay kit - by Bioz Stars,
2026-10
94/100 stars
|
Buy from Supplier |
|
Polyclonal Antibody to Janus Kinase 1 JAK1
|
Buy from Supplier |
|
Janus Kinase 1 JAK1 Antibody Biotin is an antibody conjugated to Biotin against Janus Kinase 1 JAK1
|
Buy from Supplier |
|
ELISA for estimation of Human Janus Kinase 1, JAK1 in serum, plasma and other biological fluids
|
Buy from Supplier |
Image Search Results
Journal: bioRxiv
Article Title: Spatial mapping of proteins and their activity states in cancer models by multiplex in situ PLA
doi: 10.1101/2025.07.11.662357
Figure Lengend Snippet: misPLA analyses of phosphorylation states and protein-protein interactions in SK-BR cells with or without EGF stimulation. A) Phosphorylation targets: SK-BR cells were analyzed for phosphorylation of STAT5a (pSTAT5a), STAT3 (pSTAT3), AKT (pAKT), ERK (pERK), and EGFR (pEGFR), under unstimulated and EGF-stimulated conditions. All targets were visualized three at a time in sequential detection cycles and are shown simultaneously (upper panels, “All targets”) and subsequently as individual channels. PLA signals (red, cyan, green, purple) reflect activated protein states detected via dual-recognition proximity ligation. DAPI (blue) labels nuclei. Scale bars = 50 µm. B) Protein-protein interactions: Visualization of the following protein-protein interactions investigated by misPLA in unstimulated and EGF-stimulated SK-BR cells: MEK1–ERK2, GRB2–MEK1, EGFR–GRB2, STAT3–STAT5a, JAK1–JAK3, JAK1–PI3K, JAK2–STAT5a, JAK1–STAT3, and JAK2–JAK3. Upper panels (“All targets”) represent simultaneous visualization of all targets, imaged three at a time in sequential detection cycles, followed by separated signals per interaction. Scale bars = 50 µm.
Article Snippet: The following primary antibodies were used for Western blotting:
Techniques: Phospho-proteomics, Protein-Protein interactions, Ligation
Journal: bioRxiv
Article Title: Spatial mapping of proteins and their activity states in cancer models by multiplex in situ PLA
doi: 10.1101/2025.07.11.662357
Figure Lengend Snippet: misPLA mapping of signaling interactions in a lymph-node Hodgkin lymphoma, mixed cellularity (right neck); Hodgkin lymphoma, lymphocyte-depleted (neck); Hodgkin lymphoma, lymphocyte-predominant (left neck); Hodgkin lymphoma, mixed cellularity (left neck); and thymoma type B3 (mediastinum). Top row (visualization cycle 1) displays MEK1–ERK2 (FITC), EGFR–GRB2 (Cy5) and GRB2–MEK1 (Cy3N) together with DAPI. Middle row (cycle 2) shows STAT3–STAT5a (FITC), JAK1–JAK3 (Cy5) and JAK1–PI3Kp85 (Cy3N). Bottom row (cycle 3) presents JAK2– STAT5a (FITC), JAK2–JAK3 (Cy5) and JAK1–STAT3 (Cy3N). All nine pairs of antibody-oligonucleotide conjugates were applied and then amplified in a single incubation. The RCA products were revealed using detection oligonucleotides conjugated with three fluorophores in three visualization cycles. A standard three-channel fluorescence microscope was used with identical settings for all three fluorophores. Scale bars, 50 µm.
Article Snippet: The following primary antibodies were used for Western blotting:
Techniques: Amplification, Incubation, Fluorescence, Microscopy
Journal: Nature Communications
Article Title: Metal-organic polyhedra maintain the self-renewal of embryonic stem cells
doi: 10.1038/s41467-025-63811-6
Figure Lengend Snippet: A The photo of MOP-1 aqueous solution (left). Monodisperse structure of MOP-1 in H 2 O (right). Color codes: V, green; O, red; C, gray; N, blue; Cl, bright blue. The large pink sphere represents the free space inside the molecular cage. For clarity, H atoms were omitted. Schematic (right panel) was created with Diamond software. B Experimental and simulated PXRD patterns of MOP-1. C TEM image of MOP-1 (left). Scale bar, 20 nm. The particle size of MOP-1 in H 2 O (right). Three experiments were repeated independently with similar results. D The schematic diagram showed that the SHP-2 mediated STAT3 inactivation. Schematic diagram was created with Microsoft Office PowerPoint. E , F An in-depth mechanism investigation of mESC pluripotency control by MOP-1. Binding model from a global view of a complex composed of SHP-2 and MOP-1 illustrated by electrostatic surface potential ( E ). Binding modes are illustrated by ribbon diagrams of a complex composed of SHP-2 and MOP-1 (the left panel), a complex composed of SHP-2 with MOP (the middle panel) and a complex composed of SHP-2 with ZrMOP (the right panel). The top panel is the global view of the catalytic PTP structure of SHP-2, the bottom panel is the focused view of binding modes illustrated by the Ribbon diagrams ( F ). G Binding kinetics of MOP-1 (top panel) and MOP-2 (bottom panel) with SHP-2 were measured by the SPR assay. H The ICP-MS analysis of the binding quantity between MOPs and SHP-2 (mean ± s.e.m, n = 6). I The inhibition efficiency of SHP-2, JAK2, JAK1, SHP-1, PTP1B, Cyt c , ACP and lipase by MOP-1 at a concentration of 2 μM using enzyme assay (mean ± s.e.m, n = 3). Data in ( H ) and ( I ) are analyzed by one-way ANOVA. **** P < 0.0001, the binding between MOP-1 and SHP-2 vs. the binding between MOP-2 and SHP-2, relative activity of SHP-2 vs. relative activity of JAK2, JAK1, PTP1B, Cyt c , ACP and lipase. *** P < 0.001, relative activity of SHP-2 vs. relative activity of SHP-1.
Article Snippet: The binding kinetics and affinity of MOP-1 or MOP-2 to SHP-2 (MCE, HY-P700618), SHP-1 (MCE, HY- P71141 ),
Techniques: Software, Control, Binding Assay, SPR Assay, Inhibition, Concentration Assay, Enzymatic Assay, Activity Assay